tbuckley/cabot-search huggingface dataset:
EPID-16. OUTCOMES OF FUNDED NEURO-ONCOLOGY SUMMER RESEARCH OPPORTUNITIES FOR MEDICAL STUDENTS
Authors: J. Bryan Iorgulescu, Grace Young, Nico Kahl, Achyut Patil, Timothy Smith
Journal: Neuro-Oncology (2016)

Shrinking research funding and increased clinical pressures are contributing to a growing physician-scientist shortage in neuro-oncology. A number of funded neuro-oncology summer research fellowships are available to medical students, but the impact of such early opportunities on medical students’ career trajectories remains unknown Foundations were systematically queried to identify funded neuro-oncology summer research opportunities for medical students. Outcomes were ascertained from foundation sites, provider NPIs, LinkedIn, Doximity, institutional sites, and PubMed Foundations offering neuro-oncology funded research opportunities for medical students included the American Brain Tumor Association (165 fellows, 1991-2015), Brain Tumor Center at Memorial Sloan-Kettering Cancer Center (NIH R25 funded; 61 fellows, 2008-2013), Voices Against Brain Cancer (2 fellows, 2008), and Rudin Pediatric Neuro-Oncology Fellowship at the Weill Cornell Brain and Spine Center (2 fellows, 2014-2015, excluded due to its year-long duration). 66% of projects qualified as basic/translational research and 34% as clinical research. Follow-up information was available for 198 summer fellows; of whom 46% (92) are in practice, 34% (67) are in residency/fellowship, 17% (34) are still medical students, 1% (2) are full-time researchers, and 1% (2) entered business; together producing 2,449 publications. Of those in practice, 55% (51) have academic appointments (median 18 publications, 0-210) and 45% (41) are in private practice (median 5 publications, 0-28); in the neuro-oncology-related fields of neurosurgery (26%), oncology (5%), neurology (5%), pathology (3%), and radiation oncology (1%). Similarly, trainees were in neurosurgery (25%), internal medicine (22%), neurology (4%), pathology (4%), and radiation oncology (1%) programs Compared to historical practice patterns, medical students who participated in neuro-oncology funded summer research opportunities are more likely to be in academia and the neuro-oncology-related fields of neurosurgery, neurology, pathology, and radiation oncology. Early funding for mentored medical student research may provide substantial ‘returns-on-investment’ in terms of future neuro-oncologic research and practice.
Clinical Significance of Serum Free Light Chain Test in the First Onset of Multiple Myeloma
Authors: Pan Hong, Xiaojian Meng, Jingsong He, Wenjun Wu, Yi Li, Xiaoyan Han, Gaofeng Zheng, Yi Zhao, Donghua He, Jimin Shi, Wanzhuo Xie, Jie Zhang, Xiujin Ye, He Huang, Zhen Cai
Journal: Blood (2012)
Pre-Transplant FDG-PET Scan Lacks Prognostic Value in Chemosensitive B-Cell Non-Hodgkin Lymphoma Patients Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation.
Authors: Craig S. Sauter, Hugo Castro-Malaspina, Michael Scordo, Lauren Lechner, Wayne Cohen-Levy, Miguel-Angel Perales, Jenna D Goldberg, Sergio Giralt, Juliet N Barker, Craig H. Moskowitz
Journal: Blood (2012)
Absolute Lymphocyte Counts at the End of Induction Is a Prognostic Indicator in Childhood Acute Lymphoblastic Leukemia
Authors: Daiichiro Hasegawa, Satoshi Hirase, Hironobu Takahashi, Atsuro Saito, Aiko Kozaki, Toshiaki Ishida, Tomoko Yanai, Keiichiro Kawasaki, Noriyuki Yamamoto, Ikuko Kubokawa, Takeshi Mori, Akira Hayakawa, Noriyuki Nishimura, Kazumoto Iijima, Yoshiyuki Kosaka
Journal: Blood (2014)
Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia
Authors: Karen Thudium Mueller, Abhijit Chakraborty, Patricia A Wood, Rakesh Awasthi, Alfonso Quintas-Cardama, Xia Han, Shannon L Maude, Stephan A. Grupp, David L Porter, Noelle Frey, Katherine T. Marcucci, Bruce L Levine, Jan J. Melenhorst, Carl H June, Simon F. Lacey
Journal: Blood (2016)
High-Resolution SNP-Array Profiling of Chronic Lymphocytic Leukemia
Authors: Jennifer Edelmann, Karlheinz Holzmann, W.M. Michael Kühn, Lars Bullinger, Ina Radtke, Xiaoping Su, Jing Ma, Dirk Winkler, Andreas Buehler, Michael Hallek, James R. Downing, Stephan Stilgenbauer, Hartmut Doehner
Journal: Blood (2010)
The Ligand of Glucocorticoid-Induced TNF Receptor Is Expressed on Human Macrophages and Stimulates Proinflammatory and Anti-Tumor Effector Functions.
Authors: Mercedes Kloss, Matthias Krusch, Katrin M. Baltz, Andrea Peterfi, Ingrid Kumbier, Lothar Kanz, Helmut R. Salih
Journal: Blood (2006)
First Results of a Prospective Study on Erythropoietin Biosimilar (Epoetin zeta) Use in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Malignancies
Authors: Mauricette Michallet, Mohamad Sobh, Jeremy Monfray, Hélène Labussière-wallet, Marie Balsat, Caroline Lejeune, Sophie Ducastelle-Leprêtre, Fiorenza Barraco, Xavier Thomas, Franck E. Nicolini
Journal: Blood (2015)
Successful Peripheral Haematopoitic Autologous Stem Cells Transplants After More Than 5 Days of without Cryopreservation In Non Hodgkin Lymphoma: Asian Scenario
Authors: Sandeep Jasuja, Hemant Malhota, Neetu Kukar(Jasuja), Dinesh Gautam, Shrikant Sharma, Rajesh Sharma
Journal: Blood (2010)
Individual Treatment with Stem Cell Rescue in Patients with Germ-Cell Tumors. Results of One Centrum.
Authors: Jana Nepomucka, Jitka Abrahamova, Martin Foldyna, Zuzana Donatova, Drahomira Kordikova, Ludmila Pagacova, Jan Kalanin, Marcela Greplova, Markyta Bartova
Journal: Blood (2006)
CSIG-26. MET FUSION, AMPLIFICATION, AND/OR OVEREXPRESSION DEFINES DIFFUSELY INVASIVE TUMOR CELLS IN PEDIATRIC AND ADULT GLIOBLASTOMA
Authors: Krishanthan Vigneswaran, Renee Read, Jeffrey J. Olson, Tobey MacDonald, Stewart Neill, Michael Rossi
Journal: Neuro-Oncology (2016)

Glioblastomas (GBMs) are WHO Grade IV neoplasms of the central nervous system (CNS) that are the most common and most aggressive glioma. Genomics show that the most frequent changes in GBMs include amplification, mutation, and/or overexpression of receptor tyrosine kinases (RTKs) as well as mutations that constitutively activate the PI-3 kinase (PI3K) pathway. Current data indicates that RTK-PI3K signaling cooperates with other mutations that drive GBM pathology and confer therapeutic resistance. To best understand the factors that drive tumor growth and therapeutic resistance, we have developed a research program that utilizes primary human GBM neurosphere cultures created from surgical specimens. These GBM neurosphere cultures retain many of the defining features and mutations found in primary tumors, and, in mouse xenograft assays, they yield highly malignant invasive tumors. We currently have more than 30 GBM neurosphere lines created from tumors that have been genomically profiled for copy number abnormalities and for common mutations. In addition, neurosphere lines are subject to RNA sequencing to determine their over-all transcriptome and to identify novel and recurrent mutations in tumor cells. Through these analyses we have identified a number of copy number changes, point mutations, and gene fusions in several loci. We identified alterations in the MET gene, and found that diffusely invasive GBM cells express MET. Our sequencing data showed that MET is co-overexpressed with Class 3 Semaphorins and their receptors, genes that augment MET activity in migrating neural cells in the developing embryonic brain; these genes may cooperate with MET alterations to worsen GBM. Therefore, we propose to 1) test drugs that inhibit MET and in our models of MET-mutant GBMs, and 2) determine if MET mutations and alterations cooperate with Semaphorins to drive GBM tumor cell invasion. Our results could lead to new clinical trials of MET targeted therapies in GBM.
Fragments of Activated Coagulation Factor VIII Bind to Multiple Sites within Low-Density Lipoprotein Receptor-Related Protein.
Authors: Andrey G. Sarafanov, Evgeny M. Makogonenko, Olav M. Andersen, Alexey V. Khrenov, Irina A. Mikhailenko, Natalya M. Ananyeva, Dudley K. Strickland, Evgueni L. Saenko
Journal: Blood (2005)
Novel Molecular Imaging Detects Evidence of Altered Bone Marrow Biology in Myeloma Precursor Disease (MGUS and smoldering myeloma): A Prospective Clinical Study
Authors: Esther Tan, Liza Lindenberg, Neha Korde, Alexandra Berg, Esther Mena, Baris Turkbey, Omer Aras, Seth M. Steinberg, Brendan Weiss, Alex Minter, Mary Ann Yancey, Marcia Mulquin, Peter Choyke, Karen Kurdziel, Ola Landgren
Journal: Blood (2011)
154P Clinical trial designs for the approval of rare cancer drugs in Japan
Authors: E. Noguchi, K. Yonemori, T. Shimoi, M. Yunokawa, H.S. Okuma, A. Kawachi, A. Kitano, T. Nishikawa, A. Shimomura, C. Shimizu, Y. Takiguchi, A. Kawai, Y. Fujiwara, K. Tamura
Journal: Annals of Oncology (2016)
EPIT decreases T1D incidence in sensitized non obese diabetic mice: a likely bystander effect of EPIT-induced Tregs
Authors: Christophe M. Dupont, Benjamin Pelletier, Veronique Dhelft, Melanie Ligouis, Hugh A. Sampson, Pierre-Henri Benhamou, Lucie Mondoulet
Journal: Journal of Allergy and Clinical Immunology (2017)
Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible
Authors: M.R. Patel, J. Ellerton, M. Agrawal, M. Gordon, L. Dirix, K.-W. Lee, J. Infante, M. Schlichting, K. Chin, A.B. Apolo
Journal: Annals of Oncology (2016)
International Workshop on Hepatitis B and Liver Cancer: Special Report2
Authors: John L. Ziegler, Richard H. Adamson, Lewellys F. Barker, Joseph F. Fraumeni, John Gerin, Robert H. Purcell
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article International Workshop on Hepatitis B and Liver Cancer: Special Report Get access John L. Ziegler, M.D., John L. Ziegler, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard H. Adamson, M.D., Richard H. Adamson, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Lewellys F. Barker, M.D., Lewellys F. Barker, M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Joseph F. Fraumeni, Jr., M.D., Joseph F. Fraumeni, Jr., M.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar John Gerin, Ph.D., John Gerin, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar Robert H. Purcell Robert H. Purcell Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 3, March 1978, Page 717, https://doi.org/10.1093/jnci/60.3.717 Published: 01 March 1978 Article history Received: 19 September 1977 Accepted: 12 October 1977 Published: 01 March 1978
TMOD-15. MLN8237 TREATMENT IN AN ORTHOXENOGRAFT RODENT MODEL FOR MALIGNANT PERIPHERAL NERVE SHEATH TUMORS
Authors: Oliver Mrowczynski, Russell Payne
Journal: Neuro-Oncology (2016)

Malignant peripheral nerve sheath tumors (MPNSTs) are soft tissue sarcomas that arise from peripheral nerves and often occur in the extremities. MPNSTs arise sporadically or in the neurofibromatosis type one (NF1). NF1 is an autosomal-dominant disorder characterized by neurofibromas, cutaneous hyperpigmentation, and intellectual deficits affecting 1 in 3000 births. The lifetime risk of a person with NF1 developing MPNSTs ranges between 8-13%. MPNSTs have increased expression of the oncogene Aurora kinase A. This leads to enhanced cell proliferation, making MPNSTs extremely aggressive, with high potential for metastasis, and devastating prognosis, with five year survival estimates ranging from a dismal 15-60%. MPNSTs are currently treated with surgical resection, sometimes requiring limb amputation, as well as chemoradiation, all of which demonstrate limited effectiveness, and highlight the necessity for novel therapies. To evaluate the effectiveness of new treatments, a translationally accurate, robust, and cost-effective model is crucial. A major goal of this study was to produce an orthotopic xenograft murine MPNST model for evaluation of novel therapies, which we created by intra-neural injection of luciferase transfected MPNST cells into the mice sciatic nerve. Our model circumvents drawbacks of previous in vivo models by producing a robust tumor in the physiologically relevant microenvironment of the nerve that allows for accurate tumor burden quantification through luciferin fluorescence. Another goal of this study was to demonstrate the effectiveness of MLN8237 for MPNST treatment. MLN8237 is an aurora kinase A inhibitor that we demonstrate to decrease MPNST burden by 54%. This study provides a robust and reproducible MPNST model, allowing for the advancement of MPNST therapy. This study also demonstrates the effectiveness of MLN8237 for MPNST treatment. Together, our data has major implications on the future of MPNST research by providing a robust murine model as well providing evidence that MLN8237 is an effective treatment for MPNSTs.
Tumor Necrosis Factor-α Signaling In Sickle Cell Disease: Elevated Biomarker Levels and Genetic Associations with Disease Severity
Authors: Daniel A Dworkis, Elizabeth Klings, Nadia Solovieff, Guihua Li, Jacqueline N Milton, Stephen W. Hartley, Efthymia Melista, Jason Parente, Paola Sebastiani, Martin H. Steinberg, Clinton T. Baldwin
Journal: Blood (2010)
Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
Authors: S. Pusceddu, R. Marconcini, F. Spada, F. Cavalcoli, T. Ibrahim, M.P. Brizzi, N. Brighi, A. Faggiano, I. Puliafito, G. Delle Fave, V. Perfetti, G. Luppi, C. Carnaghi, P. Razzore, M.V. Davì, C. Cauchi, M. Duro, M. Di Maio, R. Buzzoni, D. Femia, F. De Braud
Journal: Annals of Oncology (2016)
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Authors: Malte Asshoff, Verena Petzer, Matthew R. Warr, David Haschka, Piotr Tymoszuk, Egon Demetz, Markus Seifert, Wilfried Posch, Manfred Nairz, Pat Maciejewski, Peter Fowles, Christopher J. Burns, Gregg Smith, Kay-Uwe Wagner, Guenter Weiss, J. Andrew Whitney, Igor Theurl
Journal: Blood (2017)
A prospective trial on the efficacy of a multiparametric imaging biomarker for early identification of GBM patients resistant to first- line therapy.
Authors: C. J. Galbán, T. L. Chenevert, C. R. Meyer, C. Tsien, T. S. Lawrence, L. Junck, P. C. Sundgren, T. D. Johnson, A. Rehemtulla, B. D. Ross
Journal: Journal of Clinical Oncology (2010)

2068 Background: Patients diagnosed with a malignant glioma continue to have a poor prognosis. Our previous research has shown that therapeutic-associated alterations in tumor cellularity and hemodynamic as determined by applying an innovative, voxel-by-voxel method of image analysis called parametric response mapping (PRM) to serial diffusion and perfusion MRI maps correlate with patient overall survival. The aim of this study was to assess whether a composite diffusion/perfusion model of the quantified PRM metrics may help in the early assessment of treatment resistance in patients with high grade glioma. Methods: Patients with high grade glioma received concurrent chemoradiation. Apparent diffusion coefficient (ADC) and relative cerebral blood volume (rCBV) maps were acquired prior to chemoradiation and at week 3 during treatment on a prospective IRB-approved study. Clinical and conventional MR parameters, including average baseline ADC and rCBV, were evaluated as prognostic indicators of 1-year and overall survival and compared to PRM image analysis. Results: In 45 patients, median survival was found to be 14.9 months with 56% of patients living past one year. Baseline ADC was the only single metric not found to be predictive of survival at one year, whereas in a multivariate analysis PRMADC+ and PRMrCBV− had a stronger correlation to one-year and overall survival than baseline rCBV. Overall, a composite metric of PRMADC+ and PRMrCBV− had the strongest correlation with 1-year survival and a median overall survival of 5.5 (95% confidence interval = 4.4-6.6) months for patients resistant to first-line therapy. Conclusions: Inclusion of PRMADC+ and PRMrCBV− into a single metric has the potential for providing an early assessment of patients resistant to chemoradiation thus providing an early opportunity for salvage therapy. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration ImBio, LLC
Binding Properties of a Human Anti-Ib ScFv Antibody (HIb-1) to Native, Recombinant, and Transgenicially Expressed Human Platelet GP Ibα Antigen.
Authors: Antony Y. Kim, George Bell, Joshua Lovelock, Elizabeth G. Favre, Tapan K. Biswas, Mohammed Yousef, Jonathan L. Miller
Journal: Blood (2005)
The effect of topotecan in advanced intraocular retinoblastoma with manageable toxicity.
Authors: I. A. Qaddoumi, C. Billups, C. F. Stewart, J. Wu, K. Helton, B. McCarville, T. E. Merchant, R. C. Brennan, B. Haik, C. Rodriguez-Galindo, M. W. Wilson
Journal: Journal of Clinical Oncology (2011)

9540 Background: There is a need to identify new effective chemotherapeutic agents for the treatment of intraocular retinoblastoma (RB). Methods: An institutional protocol (RET5) for the study and treatment of patients with intraocular RB stratified patients into three groups according to laterality and stage of disease. The primary objective of RET5 was to estimate the response of window therapy for patients with bilateral RB in whom at least one eye was Reese-Ellsworth IV or V. Window therapy consisted of 2 courses of vincristine and topotecan (VT with G-CSF support). Patients with ≥ partial response received 3 more courses of VT alternating with 6 courses of vincristine and carboplatin. The topotecan dose started at 3 mg/m2/day, and was adjusted to attain a target systemic exposure of 140 ± 20 ng/ml*hr. Carboplatin was administered to achieve an area under the curve of 6.5 mg/ml/min. The dose of vincristine dose was 0.05 mg/kg if age at diagnosis < 12 months and 1.5mg/m2 if age at diagnosis > 12 months. Results: From 2/2005 until 6/2010, a total of 27 patients were treated VT window therapy. The median age at enrollment was 8.1 months (range, 0.7 to 22.1 months). Twenty-four of 27 patients (88.9%) responded to the VT window with a response rate 88.9% and a 95% Blyth-Still-Casella CI, 71.3%-96.9%. Hematologic toxicity in the form of grade 4 neutropenia (n=27), grade 3 anemia (n=19) and grade 3-4 thrombocytopenia (n=16) were observed during the VT window. Thirteen patients developed grade 3 non-hematologic toxicity. G-CSF support was added after treating 10 patients. Patients treated with GCSF (n=17) had a significant shorter duration of grade 4 neutropenia (median, 7 days) compared to patients without G-CSF (n=10) (median, 24 days) (Wilcoxon rank sum test p<0.0001). Conclusions: Topotecan is an effective agent in the treatment of advanced intraocular RB. The use of GCSF alleviated toxicity, especially the duration of grade 4 neutropenia.
A master regulator of tight junctions involved in hepatitis C virus entry and pathogenesis
Authors: Solène Denolly, François‐Loïc Cosset
Journal: Hepatology (2017)

1CIRI–International Center for Infectiology ResearchTeam EVIR, Inserm, U1111, Université Claude Bernard Lyon‐1, CNRS UMR5308, Ecole Normale Supérieure de Lyon, Université de LyonLyonFrance
S-2209, a Novel, Non-Boronic Proteasome Inhibitor, Induces Apoptosis and Cell Growth Arrest in Multiple Myeloma Cells.
Authors: Philipp Baumann, Karin Mueller, Sonja Mandl-Weber, Helmut Ostermann, Ralf Schmidmaier, Fuat Oduncu, Johann Leban, Robert Doblhofer, Astrid Ammendola, Roland Baumgartner
Journal: Blood (2007)
Complete Tumor Responses in Lymphoma Patients Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein Barr Virus (EBV) - Latent Membrane Proteins
Authors: Catherine M. Bollard, Stephen Gottschalk, Andrea M. Sheehan, George Carrum, Hao Liu, Barbara Pro, Luis Fayad, Anas Younes, Martha Mims, Adrian P. Gee, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop
Journal: Blood (2011)
The NK Cell MicroRNA Transcriptome Defined by Next-Generation Sequencing Identifies IL-15-Signaled Alterations In Mature MiR-223 Expression, and MiR-223 as a Potential Regulator of Murine Granzyme B
Authors: Todd A Fehniger, Todd Wylie, Elizabeth Germino, Jeffrey W Leong, Vincent J Magrini, Sunita Koul, Catherine R Keppel, Stephanie E Schneider, Daniel C Koboldt, Ryan P Sullivan, Michael E Heinz, Seth D Crosby, Rakesh Nagarajan, Giridharan Ramsingh, Daniel C Link, Timothy J Ley, Elaine R Mardis
Journal: Blood (2010)
Rituximab May Allow To Improve Multi-Organ Involvement in Patients with cGVHD.
Authors: Francesco F. Zaja, Andrea A. Bacigalupo, Alberto A. Bosi, Rosanna R. Scimè, Giovanna G. Milone, Michele M. Falda, C. Vener, D. Laszlo, E. P. Alessandrino, F. Narni, S. Sica, A. Olivieri, Alessandra A. Sperotto, Renato R. Fanin
Journal: Blood (2005)
A Prospective, Randomised Trial of Chlorambucil, Mitoxantrone and Dexamethasone (CMD) Versus Fludarabine, Mitoxantrone and Dexamethasone (FMD) for Advanced Follicular Lymphoma (Real Grades I-III, Stages III/IV).
Authors: Andrew Haynes, Andrew McMillan, Andrew Jack, Wendi Qian, Ira Jakupovic, Paul Smith, Archie Prentice
Journal: Blood (2006)
Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility
Authors: Masaki Takeuchi, Nobuhisa Mizuki, Akira Meguro, Michael J Ombrello, Yohei Kirino, Colleen Satorius, Julie Le, Mary Blake, Burak Erer, Tatsukata Kawagoe, Duran Ustek, Ilknur Tugal-Tutkun, Emire Seyahi, Yilmaz Ozyazgan, Inês Sousa, Fereydoun Davatchi, Vânia Francisco, Farhad Shahram, Bahar Sadeghi Abdollahi, Abdolhadi Nadji, Niloofar Mojarad Shafiee, Fahmida Ghaderibarmi, Shigeaki Ohno, Atsuhisa Ueda, Yoshiaki Ishigatsubo, Massimo Gadina, Sofia A Oliveira, Ahmet Gül, Daniel L Kastner, Elaine F Remmers
Journal: Nature Genetics (2017)
METB-09. NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) IS REQUIRED TO MAINTAIN CELLULAR METABOLISM IN GLIOBLASTOMA
Authors: Frances Wheeler, Denise Herpai
Journal: Neuro-Oncology (2016)

Nicotinamide adenine dinucleotide (NAD) is central to cellular metabolism, both as a cofactor and as an enzymatic substrate. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate limiting enzyme in the NAD salvage pathway, generating the NAD precursor nicotinamide mononucleotide from nicotinamide. We found that NAMPT expression is higher in glioblastoma (GBM) cell lines compared to normal astrocytes and is expressed at higher levels in GBM tissue samples vs. non-malignant brain. Pharmacological blockade of NAMPT reduced GBM cells viability in a time- and dose-dependent manner. Metabolic analysis of a GBM cell line treated with the NAMPT inhibitor FK866 revealed a profile of induced changes in energy metabolism. In the glycolysis pathway, NAD+is required for GAPDH function. Inhibition of NAMPT resulted in increased metabolites above the GAPDH reaction and and a decrease in metabolites below the GAPDH step. Metabolic flux analysis further demonstrated that GBM cell lines treated with NAMPT inhibitor have decreased glycolytic capacity. In the TCA cycle, NAMPT inhibition resulted in increased metabolites early in the cycle and decreased metabolites late in the cycle, indicating a decreased ability to complete the TCA cycle. As a result, GBM cells treated with a NAMPT inhibitor have severely impaired mitochondrial capacity. NAMPT blockade also protected cells from the effects of glucose withdrawal, indicating a role in metabolic stress. To gain further insight into the mechanisms associated with NAMPT inhibition, RNA-Seq was performed on U-251 GBM cells treated with FK866. Regulation of phosphorylation and kinase activity, cell migration, and gene regulation were among the most down regulated pathways and cell adhesion, apoptosis, gene regulation, and kinase activity were the most upregulated by NAMPT inhibition. These data provide critical insight into the role of NAD synthesis in GBM energy metabolism and the potential for NAMPT inhibition as a therapeutic option for GBM.